Roche claims midstage win for obesity injectable Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

#weightloss #obesity #drugdevelopment #Roche #obesityinjectable #phase2results #dualGIPGLP1agonist #phase3programme #CT388 #CarmotTherapeutics #BMI #GLP1directedmedicines #EliLilly #GIPGLP1activity #NovoNordisk #GLP1drug #obesitycategory #IQVIA #ZealandPharma
zurl.co/nATCt